In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

Acta Neuropathologica

Volumn 125, Issue 5, 2013, Pages 671-681

  Kreth, Simone ^a   Limbeck, Elisabeth ^a   Hinske, Ludwig C ^a   Schütz, Stefanie V ^a   Thon, Niklas ^a   Hoefig, Kai ^b   Egensperger, Rupert ^a   Kreth, Friedrich W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Alternative polyadenylation; Glioblastoma; MGMT; MiRNA

Indexed keywords

GLYCINE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MIR 181D; MIR 648; MIR 767 3P; THREONINE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; TEMOZOLOMIDE;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CANCER GENETICS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; METHYLATION; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; RNA DEGRADATION; RNA TRANSLATION; TRANSCRIPTION ELONGATION; BRAIN TUMOR; CULTURE TECHNIQUE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; MICRORNAS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYADENYLATION; PROMOTER REGIONS, GENETIC;

EID: 84886688520     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1081-1     Document Type: Article

References (34)

1. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124(4):547-560. doi:10.1007/s00401-012-1016-2
2. McLendon, Friedman A, Bigner D et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068. doi:10.1038/nature07385
3. Di Giammartino DC, Nishida K, Manley JL (2011) Mechanisms and consequences of alternative polyadenylation. Mol Cell 43(6):853-866. doi:10.1016/j.molcel.2011.08.017
4. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11(4):348-356. doi:10.1215/15228 517-2009-001
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003. doi:10.1056/NEJMoa043331
6. Helfer S, Schott J, Stoecklin G, Forstemann K (2012) AU-rich element-mediated mRNA decay can occur independently of the miRNA machinery in mouse embryonic fibroblasts and Drosophila S2-cells. PLoS One 7(1):e28907. doi:10.1371/journal.pone.0028907
7. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96(3):766-776. doi: 10.1111/j.1471-4159.2005.03583.x
8. Hu J, Lutz CS, Wilusz J, Tian B (2005) Bioinformatic identification of candidate cis-regulatory elements involved in human mRNA polyadenylation. RNA 11(10):1485-1493. doi:10.1261/rna.2107305
9. Ji Z, Lee JY, Pan Z, Jiang B, Tian B (2009) Progressive lengthening of 30 untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. Proc Natl Acad Sci USA 106(17):7028-7033. doi:10.1073/pnas.0900028106
10. Ji Z, Tian B (2009) Reprogramming of 30 untranslated regions of mRNAs by alternative polyadenylation in generation of pluripotent stem cells from different cell types. PLoS One 4(12):e8419. doi:10.1371/journal.pone.0008419
11. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS (2004) Human MicroRNA targets. PLoS Biol 2(11):e363. doi: 10.1371/journal.pbio.0020363
12. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6(8):1079-1099. doi:10.1016/j.dnarep.2007.03.008
13. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11(3):281-291. doi:10.1215/15228517-2008-090
14. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 18(15):4070-4079. doi:10.1158/1078-0432.CCR-12-0560
15. Kreth S, Heyn J, Grau S, Kretzschmar HA, Egensperger R, Kreth FW (2010) Identification of valid endogenous control genes for determining gene expression in human glioma. Neuro Oncol 12(6):570-579. doi:10.1093/neuonc/nop072
16. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW (2011) O-methylguanine- DNAmethyltransferase(MGMT)mRNAexpression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 6(2):e17156. doi:10.1371/journal.pone.0017156
17. Kreth S, Thon N, Kreth FW (2012) Epigenetics in human gliomas. Cancer Lett. doi:10.1016/j.canlet.2012.04.008
18. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T (2007) Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 67(18): 8952-8959. doi:10.1158/0008-5472.CAN-06-3820
19. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15-20. doi:10.1016/j.cell.2004.12.035
20. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838. doi:10.1038/nature03702
21. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121(5):651-661. doi:10.1007/s00401-011-0803-5
22. Mayr C, Bartel DP (2009) Widespread shortening of 30UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138(4):673-684. doi:10.1016/j.cell.2009.06.016
23. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126(6):1203-1217. doi:10.1016/j.cell.2006.07.031
24. Ramakrishnan V, Kushwaha D, Koay DC, Reddy H, Mao Y, Zhou L,NgK, Zinn P,Carter B,ChenCC(2011)Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark 10(3-4):185-193. doi:10.3233/CBM-2012-0245
25. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB (2008) Proliferating cells express mRNAs with shortened 30 untranslated regions and fewer microRNA target sites. Science 320(5883): 1643-1647. doi:10.1126/science.1155390
26. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, Mills KD, Graber JH (2009) Global changes in processing of mRNA 30 untranslated regions characterize clinically distinct cancer subtypes. Cancer Res 69(24):9422-9430. doi:10.1158/0008-5472.CAN-09-2236
27. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM (2005) Animal MicroRNAs confer robustness to gene expression and have a significant impact on 30UTR evolution. Cell 123(6):1133-1146. doi:10.1016/j.cell.2005.11.023
28. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459-466. doi:10.1016/S1470-2045(09)70025-7
29. Szeliga M, Zgrzywa A, Obara-Michlewska M, Albrecht J (2012) Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. J Neurochem 123(3):428-436. doi:10.1111/j.1471-4159.2012. 07917.x
30. von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21(1):74-87. doi: 10.1111/j.1750-3639.2010.00454.x
31. Wang X, El Naqa IM (2008) Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24(3):325-332. doi:10.1093/ bioinformatics/btm595
32. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507. doi:10.1056/NEJMra0708126
33. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol 14(6):712-719. doi:10.1093/neuonc/nos089
34. Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, Matsukura S, Matsuo S, Joh K, Mukai T (2005) The essential role of histone H3Lys9 di-methylation andMeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 137(3):431-440. doi:10.1093/jb/mvi048